Antengene Advances Next-Gen ADC, TCE Pipeline with AACR 2026 Data
Event summary
- Antengene will present preclinical data at AACR 2026 on three programs: ATG-125 (B7-H3 x PD-L1 ADC), ATG-106 (CDH6 x CD3 TCE), and ATG-112 (ALPPL2 x CD3 TCE).
- ATG-125 demonstrated superior antitumor activity compared to single-target ADCs in xenograft models.
- ATG-106 showed a favorable cytokine profile in preclinical models, potentially mitigating cytokine release syndrome.
- The AnTenGager™ platform is designed for low-expressing targets with fast on/off kinetics to minimize CRS and enhance efficacy.
The big picture
Antengene's focus on next-generation ADCs and TCEs reflects the ongoing shift towards more targeted and personalized cancer therapies. The company's AnTenGager™ platform represents a strategic bet on engineering T-cell engagers with improved safety profiles, addressing a key limitation of current therapies. The AACR presentations provide early validation of this platform and its potential to expand Antengene’s pipeline beyond its existing commercial assets.
What we're watching
- Clinical Translation
- The success of these preclinical findings will hinge on translating the observed efficacy and safety profile into clinical trials, particularly regarding cytokine release syndrome management for the TCE programs.
- Platform Validation
- Antengene's AnTenGager™ platform's versatility will be tested as it expands beyond these initial targets, demonstrating its broad applicability across various cancers.
- Competitive Landscape
- The ADC and TCE fields are increasingly crowded; Antengene will need to differentiate its programs through superior efficacy, safety, or target selection to secure market share.
Related topics